125
Participants
Start Date
February 29, 2004
Primary Completion Date
December 31, 2006
Study Completion Date
December 31, 2006
Ixabepilone
Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
Local Institution, La Verne
Local Institution, Meriden
Local Institution, Jacksonville
Local Institution, Baltimore
Local Institution, Boston
Local Institution, New York
Local Institution, Asheville
Local Institution, Charlotte
Local Institution, Pittsburgh
Local Institution, Providence
Local Institution, Chattanooga
Local Institution, Jackson
Local Institution, Knoxville
Local Institution, Nashville
Local Institution, Houston
Local Institution, San Antonio
Local Institution, Salt Lake City
Local Institution, Buenos Aires
Local Institution, Santa Fe
Local Institution, Montreal
Local Institution, Besançon
Local Institution, Bobigny
Local Institution, Clermont-Ferrand
Local Institution, Dijon
Local Institution, Lyon
Local Institution, Marseille
Local Institution, Vandœuvre-lès-Nancy
Local Institution, Frankfurt
Local Institution, Frankfurt Hoechst
Local Institution, Mérida
Local Institution, Chihuahua City
Local Institution, Distrito Federal
Local Institution, Amsterdam
Local Institution, Leiden
Local Institution, Oslo
Local Institution, Trondheim
Local Institution, Port Elizabeth
Local Institution, Fichardtpark
Local Institution, Pretoria
Local Institution, Overport
Local Institution, Panorama
Local Institution, Helsingborg
Local Institution, Lund
Local Institution, Malmo
Local Institution, Stockholm
Lead Sponsor
R-Pharm
INDUSTRY